Current understanding of the role and regulation of miRNAs in Burkitt lymphoma

IF 3.9 Q2 ONCOLOGY

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2018-05-11 DOI:10.2147/BLCTT.S129618

A. Videtta, V. Malagnino, G. De Falco

引用次数: 1

Abstract

Since its discovery in 1958, Burkitt lymphoma (BL) has been extensively studied and has become a model for tumorigenesis, but its pathogenesis has not been completely explained and understood yet. The aim of this review was to summarize the current knowledge about BL and, in particular, to discuss the role of miRNAs in its pathogenesis and their possible use as diagnostic and prognostic indicators. The impact of viral-encoded miRNAs is also discussed, with the Epstein–Barr infection being almost invariably detected in the endemic variant of this tumor.

查看原文本刊更多论文

目前对mirna在伯基特淋巴瘤中的作用和调控的了解

自1958年发现伯基特淋巴瘤(Burkitt lymphoma, BL)以来，人们对其进行了广泛的研究，并已成为肿瘤发生的一种模式，但其发病机制尚未得到完全的解释和理解。这篇综述的目的是总结目前关于BL的知识，特别是讨论mirna在其发病机制中的作用以及它们作为诊断和预后指标的可能用途。本文还讨论了病毒编码mirna的影响，在这种肿瘤的地方性变异中几乎总是检测到Epstein-Barr感染。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood and Lymphatic Cancer-Targets and Therapy ONCOLOGY-

自引率

7.10%

发文量

审稿时长

16 weeks

期刊介绍： Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations.